Security Snapshot

Alaunos Therapeutics, Inc. - Common Stock, par value $0.001 per share (TCRT) Institutional Ownership

CUSIP: 98973P309

13F Institutional Holders and Ownership History from Q2 2024 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

29

Shares (Excl. Options)

90.38KFull value: 90,383 · shares · 30 Jun 2026

Price

$2.26

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock, par value $0.001 per share
Symbol
TCRT on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
90,383
Latest holder snapshot 5 signals
Total 13F value
$204,421
Portfolio coverage rank
0%
Share change
-35,726
Value change
-$101,229
Number of holders
29
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
5,152,062
SEC-reported price per share
$3.03
Insider filing price
$3.03
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • TCRT - Alaunos Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 98973P309.
  • 29 institutions reported positions in Q2 2026.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 28 to 29 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $359.54KFull value: $359,538 · USD · 31 Mar 2026
    to
    $204.42KFull value: $204,421 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 29 institutions filings for Q2 2026.

Open SEC evidence

Security key

98973P309

13F reference period

Q2 2026

13F holders

29

13D/G owners

3

CIK / CUSIP context first

Open Q2 2026 holders TCRT full holder history Alaunos Therapeutics, Inc. SEC filings Alaunos Therapeutics, Inc. company facts Alaunos Therapeutics, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
3
Security
TCRT
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Fairmount Funds Management LLC 20% $772,910 858,789 Fairmount Funds Management LLC 13 Oct 2026
Postma Robert W 10% +11% $463,222 +$283,406 514,691 +158% Postma Robert W 13 Oct 2026
Price Adrian 8.6% 0% $491,559 189,061 0% Price Adrian 24 Feb 2026
As of 30 Jun 2026, 29 institutional investors reported holding
90.38KFull value: 90,383 · shares · 30 Jun 2026
shares of Alaunos Therapeutics, Inc. - Common Stock, par value $0.001 per share (TCRT). This represents 1.8% of the company’s total
5.15MFull value: 5,152,062 · shares · Stored outstanding share count
outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
10
Headline period
Q2 2026
Rows shown
1-10 of 10
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 149 $133 -$348 $0.90 6
2026 Q2 90,383 $204,421 -$101,229 $2.26 29
2026 Q1 125,752 $359,538 +$50,026 $2.86 28
2025 Q4 108,542 $349,893 +$139,293 $3.23 26
2025 Q3 65,224 $158,311 -$15,260 $2.41 24
2025 Q2 70,942 $344,079 +$2,573 $4.85 25
2025 Q1 70,134 $102,359 -$2,277 $1.47 25
2024 Q4 72,015 $136,970 -$361,475 $1.90 28
2024 Q3 192,061 $622,752 +$549,975 $3.22 28
2024 Q2 37 $25 +$25 $0.68 3
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .